Novo Nordisk A/S focuses on the design, manufacture, and marketing of pharmaceutical products, with 92.6% of sales from diabetes and obesity treatments and 7.4% from rare disease therapies, including hemophilia and hormonal disorders. Geographically, sales are distributed as follows: 54.9% in the United States, 21.9% in Europe-Middle East-Africa, 7.2% in China, 3.9% in North America, and 12.1% in other regions.
